Literature DB >> 25610096

The Levels of Serum C-Reactive Protein, Beta 2 Microglobulin, Ferritin, Lactate Dehydrogenase and Some Specific Proteins in Patients with Non-Hodgkin's Lymphoma Before and After Treatment.

Rahsan Yildirim1, Mehmet Gundogdu1, Fuat Erdem1, Lhami Kiki1, Mehmet Bilici1.   

Abstract

OBJECTIVE: The aim of this study was to measure serum C reactive protein, β2 microglobulin, ferritin, lactate dehydrogenase, complement 3, complement 4, immunoglobulin A, immunoglobulin M, immunoglobulin G and transferrin levels in patients with Non-Hodgkin Lymphoma before and after treatment, and to determine whether any differences occur with treatment, investigate relationship between these parameters and systemic symptoms, and to determine whether they could be used as tumor markers.
MATERIALS AND METHODS: The parameters listed above were studied before and after treatment in sera of 27 patients with the diagnosis of Non-Hodgkin Lymphoma who admitted to our department. Of the patients, 10 (37%) were females and 17 (63%) were males. Mean age was 57.7 ± 16.5 (19-82) years. The subjects were newly diagnosed and treatment.
RESULTS: Post-treatment serum ferritin and CRP levels were found to be significantly decreased in patients with NHL compared to pre-treatment levels (p=0.009 and p=0.015, respectively). In addition, ferritin levels measured before treatment were significantly lower in subjects with B symptoms than those without B symptoms (p=0.02). IgA levels of patients with B symptom were significantly increased compared to those without B symptoms following treatment (p=0.03).
CONCLUSIONS: We are in the opinion that serum ferritin and CRP parameters may be used as tumor markers and may be indicators in the efficacy evaluation of treatment in Non-Hodgkin's Lymphoma.

Entities:  

Keywords:  Beta 2 microglobulin; C-reactive protein; Ferritin; Lactate dehydrogenase; Non-Hodgkin Lymphoma; Serum specific protein

Year:  2009        PMID: 25610096      PMCID: PMC4261265     

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  9 in total

1.  The systemic inflammatory response predicts overall and cancer specific survival in patients with malignant lymphoma.

Authors:  Maqsood M Elahi; Donald C McMillan; Colin S McArdle; Wilson J Angerson; Michael Soukop; Jennie Johnstone; Naveed Sattar
Journal:  Med Sci Monit       Date:  2005-02

Review 2.  The acute phase response.

Authors:  H Baumann; J Gauldie
Journal:  Immunol Today       Date:  1994-02

Review 3.  A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells.

Authors:  C E Hack; G J Wolbink; C Schalkwijk; H Speijer; W T Hermens; H van den Bosch
Journal:  Immunol Today       Date:  1997-03

4.  Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas: findings in a multicenter study and experience in selected patients.

Authors:  J A Child; B Spati; S Illingworth; D Barnard; S Corbett; A V Simmons; J Stone; T S Worthy; E H Cooper
Journal:  Cancer       Date:  1980-01-15       Impact factor: 6.860

5.  Clinical efficacy of an automated high-sensitivity C-reactive protein assay.

Authors:  N Rifai; R P Tracy; P M Ridker
Journal:  Clin Chem       Date:  1999-12       Impact factor: 8.327

6.  [Clinical value of combined detection of LDH, TPS, CEA and beta2-MG in patients with non- Hodgkin's lymphoma].

Authors:  Wei Chen; Rong-cheng Luo; Wei-wen Fan; Shu-dong Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2006-02

7.  Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.

Authors:  P Litam; F Swan; F Cabanillas; S L Tucker; P McLaughlin; F B Hagemeister; M A Rodriguez; W S Velasquez
Journal:  Ann Intern Med       Date:  1991-05-15       Impact factor: 25.391

8.  Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications.

Authors:  W L Roberts; R Sedrick; L Moulton; A Spencer; N Rifai
Journal:  Clin Chem       Date:  2000-04       Impact factor: 8.327

9.  Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.

Authors:  A N Pavlidis; J Kalef-Ezra; L C Bourantas; A Lambrou; A Mavridis
Journal:  Int J Biol Markers       Date:  1993 Jan-Mar       Impact factor: 3.248

  9 in total
  1 in total

1.  High serum erythropoietin and ferritin levels in conjunction with anemia response in malignant lymphoma.

Authors:  Sofia Omari; Alhossain Khalafallah; Mahmoud Ayesh; Ismail Matalka; Raji Al-Hadithi
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-05-16       Impact factor: 2.576

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.